Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis. (2022)

Peer-Reviewed Study · Zhao CC, Zhai YJ, Hu ZJ, Huo Y, Li ZQ, Zhu GJ · September 26, 2022

Zhao CC et al., 2022-09-26: Systematic review and meta-analysis of 15 studies and 832 vasodilatory-shock patients reporting lower mortality with methylene blue plus vasopressors.

Pooled data demonstrated that administration of MB along with vasopressors significantly reduced mortality [odds ratio (OR) 0.54, 95% confidence interval (CI) 0.34 to 0.85, P = 0.008

Zhao CC et al., 2022-09-26: Systematic review and meta-analysis of 15 studies and 832 vasodilatory-shock patients reporting lower mortality with methylene blue plus vasopressors. C5. Lead verified: prompt said 'Zhao C, Zhai Y, Hu Z'; the record's author string is Zhao CC, Zhai YJ, Hu ZJ, Huo Y, Li ZQ, Zhu GJ. Front Med (Lausanne) 2022;9:950596. Study type: systematic review and meta-analysis, 15 studies, N=832, searching MEDLINE/PubMed, Embase, Web of Science, Cochrane, CNKI, CBM and Wanfang with no language restriction. Comparator: control (vasopressors without MB). Authors declare no commercial or financial conflicts. Note for the verification pass: the included studies are observational and interventional, so the pooled mortality estimate is not a purely randomized one; the 2026 RCT-only meta-analysis (MTI-47) does not reproduce a mortality benefit. Study type: review.